A cost-effectiveness analysis of deucravacitinib vs. apremilast in moderate-to-severe psoriasis patients in Japan

Deucravacitinib is cost-effective compared to apremilast in patients with moderate-to-severe plaque psoriasis in Japan, primarily driven by improvements in health-related quality of life associated with a more favorable PASI response. This conclusion is supported by extensive sensitivity and scenario analyses.